Riskpilot← Back to searchSign inGet full accessOxion Biologics AB
ABActiveOrg 5593100927StockholmResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20213 employees
Revenue 2024
SEK 2,9M
+2669% vs 2023
EBITDA margin
-716.2%
+44% vs 2023
Equity ratio
76.5%
Financial strength
Net profit 2024
SEK -7,3M
+80% vs 2023
| Revenue | SEK 2,9M | +2669% |
| EBITDA | SEK -20,4M | +44% |
| Net profit | SEK -7,3M | +80% |
| Total assets | SEK 46,7M | +100% |
| Equity | SEK 35,7M | +71% |
| Employees | 3 | — |
Legal name
Oxion Biologics AB
Org number
5593100927
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31 mars 2021
Share capital
SEK 35 714
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning och utveckling av immunmodulerande läkemedel samt därmed förenlig verksamhet.
Address
Stockholm
Email
cheng.xu@oxionbio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 103 | 2 852 |
| Staff expenses | — | −0 | −1 658 | — | −6 191 |
| EBITDA | −125 | −125 | −6 797 | −36 694 | −20 428 |
| Depreciation & amort. | −0 | −0 | — | −0 | — |
| EBIT | −125 | −125 | −6 797 | −36 694 | −20 428 |
| Net financials | — | 0 | — | −14 | −39 |
| Profit before tax | −125 | −125 | −6 797 | −36 707 | −20 467 |
| Tax | −0 | −0 | — | −0 | 13 190 |
| Net profit | −125 | −125 | −6 797 | −36 707 | −7 277 |
| Item | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 9 900 | 9 900 | 18 023 | 23 338 | 46 654 |
| Equity | 9 900 | 9 900 | 17 603 | 20 923 | 35 700 |
| Long-term debt | 0 | 0 | — | 0 | — |
| Short-term debt | 0 | 0 | 420 | 2 415 | 10 954 |
| Total debt | — | 0 | 420 | 2 415 | 10 954 |
EBITDA margin
-716.2%
This company
15.8%
Market median
-4633% vs market
20212024
Equity ratio
76.5%
This company
38.2%
Market median
+100% vs market
20212024
Return on equity
-20.4%
This company
18.4%
Market median
-211% vs market
20212024
Net profit margin
-255.1%
This company
8.1%
Market median
-3249% vs market
20212024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20212024
Debt / equity
0.31×
This company
0.62×
Market median
+50% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-03-31 – 2021-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-03-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
RG Chief Executive Officer | Chief Executive Officer | 2022 |
PÅ Audit | Audit | 2021 |
AU Chief Auditor | Chief Auditor | 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2026 | |
| Board of Directors | 2026 | |
| Chairman | 2025 | |
| Former (4) | ||
| Board of Directors | 2021 – 2021 | |
| Chairman | 2021 – 2025 | |
| Deputy Board Member | 2021 – 2021 | |
| Board of Directors | 2022 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Oxion Biologics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robin Gustav Oskar Fröbom | Chief Executive Officer | 0 companies |
| Per Åke Bois | Audit | 0 companies |
| Anne-Louise Ulla Margaretha Palm | Chief Auditor | 0 companies |
| David Glavonjic | Board of Directors | 0 companies |
| William Francis Doyle | Board of Directors | 0 companies |
| Anna-Carina B Helander Anderson | Chairman | 0 companies |
| Jessica Margareta Efeoglu Nittsjö | Deputy Board Member | 0 companies |
| Matthew William Lamb | Board of Directors | 0 companies |
| Virgil Yuan Cheng Xu | Chairman | 0 companies |
| Felix Axel Otto Sellberg | Board of Directors | 0 companies |